Filed under: Uncategorized | Tagged: Exelixis, IGF-1R, phase I, SRC, XL-228, XL228
Exelixis IGF-1R/Src inhibitor XL228 effective in Phase I
Posted on October 23, 2008 by crimsoncanary
Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2- Providing a resource for information on kinase inhibitors
Blog at WordPress.com. Theme: Digg 3 Column by WP Designer
